DOCSLIB.ORG

Purity Determination of Gynalgin Bactericidal Tablets with Hplc Method

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Purity Determination of Gynalgin Bactericidal Tablets with Hplc Method Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 70 No.1 pp. 51ñ58, 2013 ISSN 0001-6837 Polish Pharmaceutical Society PURITY DETERMINATION OF GYNALGIN BACTERICIDAL TABLETS WITH HPLC METHOD WANDA BIA£ECKA1*, ANNA KULIK1, MARZENA PODOLSKA1, BARBARA KWIATKOWSKA- PUCHNIARZ1 and ALEKSANDER MAZUREK1,2 1Department of Basic and Applied Pharmacy, National Medicines Institute, 30/34 Che≥mska St., 00-725 Warszawa, Poland 2Department of Drug Chemistry, Medical University of Warsaw, 1 Banacha St., 02-097 Warszawa, Poland Abstract: The study was aimed at developing a simple HPLC method for the determination of the content of impurities in Gynalgin, a two-component preparation. A satisfactory separation was performed on 250 ◊ 4.6 mm Symmetry C8 column in a gradient elution system: mobile phase A ñ acetonitrile/buffer, pH 5.5 in 10:90, v/v proportion, and mobile phase B ñ acetonitrile/buffer, pH 5.5 in 75:25 v/v proportion. Two wavelengths: 250 nm and 315 nm were used for detection. Validation confirmed that the method was linear in a required con- centration range. The values of correlation coefficients for specific drug substances and the related impurities were as high as 0.999. The results of the purity tests proved that the method was sufficiently selective and pre- cise. Keywords: chlorquinaldol, metronidazole, 2-methyl-5-nitroimidazole, 2-aminophenol, HPLC method The combined action of multiple drug sub- method (1). On the other hand, many papers refer to stances improves therapeutic efficacy, and therefore, metronidazole tested in medicinal products (1ñ8, the number of multi-component drugs available on 10ñ13, 17, 19) or biological material (9, 14ñ16, the market has been continuously increasing. 18ñ21). A variety of methods has been applied in the Gynalgin preparation is available as vaginal tablets tests of metronidazole: spectrophotometric method and contains two drug substances: chlorquinaldol (2ñ6), NIR spectroscopy (7), voltammetric method and metronidazole. Chlorquinaldol is a derivative of (8, 9), HPTLC (10, 11), HPLC (12ñ16), UPLC-MS 8-hydroxyquinoline exhibiting bactericidal, fungi- (17, 18), NMR (19) and LC-MS (20, 21). In a num- cidal and antiprotozoal activity; metronidazole is a ber of papers, metronidazole is reported to be meas- derivative of 5-nitroimidazole with antiprotozoal ured in parallel to other drug substances. and bactericidal activity against anaerobes. No purity determinations of chlorquinaldol and The aim of the study was to develop the easiest metronidazole in medicinal products have been possible HPLC method to separate and determine reported using a single chromatographic system the content of impurities in Gynalgin medicinal (HPLC). product. Isocratic HPLC method for the purity test of EXPERIMENTAL tablets containing metronidazole is described in British Pharmacopoeia (B.P.2011). Materials Tests of purity of the substance can be found in ● Drug product: GYNALGIN ñ vaginal tablets con- B.P.2001, Ph.Eur.7.0, and Polish Pharmacopoeia taining 100 mg of chlorquinaldol and 250 mg of VIII. Neither tests of purity of chloroquinaldol metronidazole; manufactured by ICN Polfa tablets nor of the substance were found in the same RzeszÛw S.A.; batch number: 010506; expiry documents, yet the corresponding TLC tests were date: May 2009. inserted in an older source, Polish Pharmacopoeia ● Reference standards: Chlorquinaldol manufac- VI. Only one paper dealing with chloroquinaldol tured by ICN Polfa RzeszÛw S.A. batch number: was found, with the use of spectrophotometric C4011209; 2-aminophenol (impurity of chlor- * Corresponding author: e-mail: [email protected] 51 52 WANDA BIA£ECKA et al. quinaldol) manufactured by Acros Organics batch Standard solutions number: A0266307; metronidazole manufactured A methanol standard solution (mix 0.5%) was by Farchemia, batch number: 06548740; 2- prepared, 1 mL of which contained: 0.05 mg of 2- methyl-5-nitroimidazole (impurity of metronida- methyl-5-nitroimidazole, 0.05 mg of metronidazole zole) manufactured by CRS BP, batch number: (0.5% as compared to metronidazole concentration 2474. in the sample), 0.02 mg of 2-aminophenol, and 0.02 mg of chlorquinaldol (0.5% as compared to the con- Reagents and instrument centration of chlorquinaldol in the sample). ● High-purity HPLC reagents. ● Computer-controlled liquid chromatograph by Sample solutions Shimadzu, fitted with UV-VIS SPD-10AVVP One gram of pulverized tablets was weighed detector, LC-10ATVP pump system, DGU-14A and transferred to a 25 mL volumetric flask, then 15 sample degassing unit, SCL-10AVP controller, mL of methanol was added to the sample. It was and SIL-10ADVP automatic sample feeder. ultrasonicated for ca. 15 min then, agitated on a ● Chromatographic columns: Symmetry C8, 250 ◊ mechanical shaker for approx. 30 min, made up to 4.6 mm, by Waters, and Kromasil 100-5C8 250 ◊ volume with the solvent and filtered through a filter 4.6 mm, by AKZO NOBEL. with 0.45 µm mesh size. Table 1. Calibration curve parameters, correlation coefficients, detection limits (LOD) and quantitation limits (LOQ) of the analyzed sub- stances. Substance Calibration curve parameters LOD LOQ determined y = ax + b [ µg/mL] [ µg/mL] ∆ a ± a = 45745 ± 857; Sa= 333 b ± ∆b = 50136 ± 73949; S = 28768 Metronidazole b 4.30 13.02 Sy= 59567 r = 0.9999 ∆ a ± a = 134406 ± 4528; Sa= 1631 b ± ∆b = -268279 ± 109842; S = 39562 Chlorquinaldol b 1.23 3.74 Sy= 50294 r = 0.9997 ∆ a ± a = 48750 ± 726; Sa= 261 2-Methyl-5- b ± ∆b = 18635 ± 44358; S = 15977 b 1.37 4.17 nitroimidazole Sy= 20312 r = 0.9999 ∆ a ± a = 13775 ± 278; Sa= 99 b ± ∆b = 5052 ± 6446; S = 2322 2-Aminophenol b 0.71 2.14 Sy = 2954 r = 0.9999 a, b ñ regression coefficients; Sa, Sb ñ standard deviation of regression coefficients; Sy ñ standard error of the estimate; r ñ correlation coef- ficients. Table 2. Results of system precision tests. Substance Average Standard RSD determined peak area deviation [%] [a.u.] n = 6 Metronidazole 1992389 14419 0.72 Chlorquinaldol 1880307 28223 1.50 2-Methyl-5- nitroimidazole 2070600 17141 0.83 2ñAminophenol 219760 2585 1.18 Purity determination of gynalgin bactericidal tablets with HPLC method 53 Figure 1. Chromatograms of the mixture of standards at 250 nm and 315 nm wavelengh. Retention times: 2-methyl-5-nitroimidazole 5.3 min.; metronidazole 7.5 min.; 2-aminophenol 8.2 min.; chlorquinaldol 23.2 min The sample solution contained 10 mg/mL of parent drug substances. as well as peaks originating metronidazole and 4 mg/mL of chlorquinaldol . from the solvent and placebo. For the tests, the expired tablets were selected RESULTS AND DISCUSSION (1.5 years past their expiration date) with a new hav- ing more impurities. HPLC method development A variety of gradient elution systems were First, a specific HPLC system has been tested, along with numerous modifications of sought, which would provide sufficient separation mobile phases, flow rates and injection volumes. pH and quantitative determination of impurities origi- of the mobile phase influenced the 2-aminophenol nating from metronidazole and chlorquinaldol. It peak location. The following chromatographic sys- was necessary to separate 2ñaminophenol, 2- tem was finally selected for further tests with the aid methyl-5-nitroimidazole, and unidentified impuri- of gradient elution: Symmetry C8 column, 250 ◊ 4.6 ties developed in the course of stress tests from the mm; 40OC; mobile phase A ñ a mixture of acetoni- 54 WANDA BIA£ECKA et al. trile and buffer, pH 5.5 (10 : 90, v/v); mobile phase B ñ a mixture of acetonitrile and buffer, pH 5.5 (75 : 25, v/v); buffer, pH 5.5 ñ a mixture of 1,000 mL of water and 1 mL of 85% H3PO4 adjusted to pH 5.5 with 10% NaOH solution. Gradient elution: Time [min] Mobile phase B [%] 0 ñ 20 0 → 100 20 ñ 25 100 25 ñ 27 100 → 0 27 ñ 35 0 Mobile phase flow rate was 1.2 mL/min, injec- tion volume 20 µL, and detection wavelengths: 250 nm (to determine 2-aminophenol and unidentified impurities originating from chlorquinaldol) and 315 nm (to determine 2-methyl-5-nitroimidazole and other unidentified impurities originating from metronidazole) . The following system performance parameters were selected: symmetry coefficient (A10%)of metronidazole peak, which ought to be not higher than 1.5, and resolution (Rs) between the peaks for 2-aminophenol and metronidazole, not lower than 3.0. The parameters were measured with the mix 0.5% solution. Validation of the method Specificity In order to examine the method specificity, solvent, solution of excipients (placebo), solutions of identified impurities (2-methyl-5-nitroimida- zole and 2ñaminophenol) and unidentified impuri- ties (obtained in the course of stress tests) along with solutions of standard drug substances were injected onto the column. The recorded chro- matograms revealed that the peaks originating from the solvent, drug substances and excipients did not interfere with the peaks originating from Impurities originating Impurities originating from metronidazole [%] impurities.from chlorquinaldol [%] Linearity A dependence was examined between the peak areas on the chromatogram and the concentrations of specific substances and was found to be linear within the following concentrations: 0.01 mg/mL ñ 0.1 mg/mL for 2-methyl-5-nitroimi- dazole; 0.004 mg/mL ñ 0.04 mg/mL for 2-aminophenol; 1.75 0.14 0.74 0.28 1.21 0.64 13.75 12.59 1.89 3.03 0.2180.2180.2200.215 0.3070.219 0.3060.213 0.311 0.023 0.309 0.023 0.308 0.024 0.308 0.030 0.024 0.030 0.023 0.030 0.0230.01 0.061 0.030 mg/mL 0.060 0.030 0.061 0.030 0.060 ñ 0.060 0.639 0.1 0.061 0.637 mg/mL 0.646 0.634 0.066 0.638 for 0.058 0.641 metronidazole; 0.061 0.054 0.028 0.061 0.026 0.064 0.027 0.023 0.196 0.028 0.196 0.027 0.200 0.190 0.290 0.196 0.280 0.197 0.288 0.267 0.285 0.288 0.0038 0.0004 0.0002 0.0001 0.0007 0.004 0.0082 0.032 0.0036 0.01 RT 3.8 RT 4.7 RT 9.1 RT 9.2 RT 10.0 Total RT 24.4 RT 26.2 RT 28.8 Total 0.004 mg/mL ñ 0.04 mg/mL for chlorquinaldol.
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Identification of Drug Candidates That Enhance Pyrazinamide Activity from a Clinical Drug Library
    bioRxiv preprint doi: https://doi.org/10.1101/113704; this version posted March 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Identification of drug candidates that enhance pyrazinamide activity from a clinical drug library Hongxia Niub, a, Chao Mac, Peng Cuid, Wanliang Shia, Shuo Zhanga, Jie Fenga, David Sullivana, Bingdong Zhu b, Wenhong Zhangd, Ying Zhanga,d* a Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA b Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China c College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, China d Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China *Correspondence: Ying Zhang, E-Mail: [email protected] Tuberculosis (TB) remains a leading cause of morbidity and mortality globally despite the availability of the TB therapy. 1 The current TB therapy is lengthy and suboptimal, requiring a treatment time of at least 6 months for drug susceptible TB and 9-12 months (shorter Bangladesh regimen) or 18-24 months (regular regimen) for multi-drug-resistant tuberculosis (MDR-TB). 1 The lengthy therapy makes patient compliance difficult, which frequently leads to emergence of drug-resistant strains. The requirement for the prolonged treatment is thought to be due to dormant persister bacteria which are not effectively killed by the current TB drugs, except rifampin and pyrazinamide (PZA) which have higher activity against persisters.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Blindness and Neuropathy from Diiodohydroxyquin-Like Drugs: Committee on Drugs Sumner J
    Blindness and Neuropathy From Diiodohydroxyquin-Like Drugs Committee on Drugs The halogenated hydnoxyquinolines-iodochlo- eases is outweighed by the serious and often irre- rhydroxyqumn, diiodohydroxyquin, bnoxyquino- versible damage that can insidiously occur with line, and chlorquinaldol (Table 1)-were long chronic treatment of a child. thought to have little toxicity, but it is now clear Villarejos et studied the long-term use of io- that these compounds can cause serious and inre- dochlorhydroxyquin (10 mg/kg/day, six days a versible damage to the nervous system.’ Toxicity week for 16 weeks) in children from an area of is a function of dose and duration of therapy. Sin- Honduras where there was a highendemic level of gle, lange doses cause cerebral dysfunctions, char- diarrhea. Treated children had lower rates of diar- actenized by disorientation and retrograde amne- rhea than placebo or nonplacebo controls. No sia. Optic atrophy and peripheral neunopathy can neuropathy was noted even though the home of occur when moderate doses are used for more than each study subject was visited six days a week by three weeks. nurse’s aides. Because infantile diarrhea is a major Neunopathy has been reported in 12 children212 problem in many countries, the results of this and we know of three others who had taken halo- study could lead to widespread, chronic use of hal- genated hydroxyquinolines in high doses (at least ogenated hydroxyquinolines. We would be con- adult doses) and/on for more than three weeks. cerned that in such a less-controlled clinical situa- Fourteen of the 15 had loss of visual acuity; 13 had tion increases of dose and/on length of therapy permanent optic atrophy.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom Et Al
    USOO8383154B2 (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom et al. (45) Date of Patent: Feb. 26, 2013 (54) SWELLABLE DOSAGE FORM COMPRISING W W 2.3. A. 3. 2. GELLAN GUMI WO WOO1,76610 10, 2001 WO WOO2,46571 A2 6, 2002 (75) Inventors: Daniel Bar-Shalom, Kokkedal (DK); WO WO O2/49571 A2 6, 2002 Lillian Slot, Virum (DK); Gina Fischer, WO WO 03/043638 A1 5, 2003 yerlosea (DK), Pernille Heyrup WO WO 2004/096906 A1 11, 2004 Hemmingsen, Bagsvaerd (DK) WO WO 2005/007074 1, 2005 WO WO 2005/007074 A 1, 2005 (73) Assignee: Egalet A/S, Vaerlose (DK) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 JECFA, “Gellangum”. FNP 52 Addendum 4 (1996).* U.S.C. 154(b) by 1259 days. JECFA, “Talc”, FNP 52 Addendum 1 (1992).* Alterna LLC, “ElixSure, Allergy Formula', description and label (21) Appl. No.: 111596,123 directions, online (Feb. 6, 2007). Hagerström, H., “Polymer gels as pharmaceutical dosage forms'. (22) PCT Filed: May 11, 2005 comprehensive Summaries of Uppsala dissertations from the faculty of pharmacy, vol. 293 Uppsala (2003). (86). PCT No.: PCT/DK2OOS/OOO317 Lin, “Gellan Gum', U.S. Food and Drug Administration, www. inchem.org, online (Jan. 17, 2005). S371 (c)(1), Miyazaki, S., et al., “In situ-gelling gellan formulations as vehicles (2), (4) Date: Aug. 14, 2007 for oral drug delivery”. J. Control Release, vol. 60, pp. 287-295 (1999). (87) PCT Pub. No.: WO2005/107713 Rowe, Raymond C.
    [Show full text]
  • Vaginal Foreign Body Mimicking Cervical Cancer in Postmenopausal Woman – Case Study
    DOI: 10.5114/pm.2015.54348 Prz Menopauzalny 2015; 14(3): 208-210 Case report Vaginal foreign body mimicking cervical cancer in postmenopausal woman – case study Michał Ciebiera, Aneta Słabuszewska-Jóźwiak, Witold Ledowicz, Grzegorz Jakiel First Department of Gynaecology and Obstetrics, The Medical Centre of Postgraduate Education, Warsaw, Poland Abstract We present a case report of a 73-year-old, postmenopausal woman with detailed history of breast cancer and oncology treatment including tamoxifen therapy. She presented at the clinic of gynecology and obstetrics with recurrent inflammation of the urinary and genital tract and suspicion of a cervical mass. She also presented occasional abdominal complaints and malodorous vaginal discharge. These symptoms were observed in the patient for several years. Before hospitalization she received many kinds of empirical, antimicrobial treatment such as chlorquinaldol, metronidazole, nifuratel, and nystatin. She did not receive further guidance from doc- tors about the causes of ailments and further diagnostic and treatment capabilities. In our clinic a detailed diagnostic process including ultrasound transvaginal examination and a minisurgical procedure revealed the presence of a vaginal foreign body (which turned out to be a plastic, shampoo bottle cap) surrounded by a mass of inflamed tissue mimicking a cervical tumor. All symptoms and complaints subsided after surgical removal of the foreign body and antibacterial therapy with metronidazole and cefuroxime. Our study draws attention to the need of thorough gynecological care including prophylaxis, especially in the case of complaints of an intimate nature. Even trivial, frequently occurring disorders can be dangerous and require proper and responsible doc- tor’s supervision and management through the healing process.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]